Log in

NASDAQ:MLNDMillendo Therapeutics Stock Price, Forecast & News

$2.18
-0.12 (-5.22 %)
(As of 06/4/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.95
Now: $2.18
$2.32
50-Day Range
$1.47
MA: $1.81
$2.66
52-Week Range
$1.26
Now: $2.18
$15.75
Volume1.35 million shs
Average Volume1.16 million shs
Market Capitalization$41.42 million
P/E RatioN/A
Dividend YieldN/A
Beta1.53
Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; and nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia. Millendo Therapeutics, Inc. is headquartered in Ann Arbor, Michigan.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.60 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MLND
CUSIPN/A
CIKN/A
Phone734-845-9000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$290,000.00
Book Value$3.28 per share

Profitability

Net Income$-44,570,000.00

Miscellaneous

Employees37
Market Cap$41.42 million
Next Earnings Date8/10/2020 (Estimated)
OptionableNot Optionable

Receive MLND News and Ratings via Email

Sign-up to receive the latest news and ratings for MLND and its competitors with MarketBeat's FREE daily newsletter.

Millendo Therapeutics (NASDAQ:MLND) Frequently Asked Questions

How has Millendo Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Millendo Therapeutics' stock was trading at $6.58 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MLND shares have decreased by 66.9% and is now trading at $2.18. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Millendo Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Millendo Therapeutics in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Millendo Therapeutics.

When is Millendo Therapeutics' next earnings date?

Millendo Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Millendo Therapeutics.

How were Millendo Therapeutics' earnings last quarter?

Millendo Therapeutics Inc (NASDAQ:MLND) posted its quarterly earnings results on Friday, May, 8th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.02. View Millendo Therapeutics' earnings history.

What price target have analysts set for MLND?

7 Wall Street analysts have issued 12-month target prices for Millendo Therapeutics' stock. Their forecasts range from $2.00 to $26.00. On average, they expect Millendo Therapeutics' share price to reach $11.00 in the next twelve months. This suggests a possible upside of 404.6% from the stock's current price. View analysts' price targets for Millendo Therapeutics.

Has Millendo Therapeutics been receiving favorable news coverage?

News headlines about MLND stock have trended very positive on Friday, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Millendo Therapeutics earned a news impact score of 3.4 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near term. View the latest news aboutMillendo Therapeutics.

Are investors shorting Millendo Therapeutics?

Millendo Therapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 442,000 shares, an increase of 43.6% from the April 30th total of 307,900 shares. Based on an average trading volume of 800,300 shares, the short-interest ratio is presently 0.6 days. Approximately 3.4% of the shares of the company are sold short. View Millendo Therapeutics' Current Options Chain.

Who are some of Millendo Therapeutics' key competitors?

What other stocks do shareholders of Millendo Therapeutics own?

Who are Millendo Therapeutics' key executives?

Millendo Therapeutics' management team includes the following people:
  • Dr. Julia C. Owens Ph.D., CEO, Pres & Director (Age 47, Pay $702.8k)
  • Mr. Louis J. Arcudi III, M.B.A., MBA, Chief Financial Officer (Age 59, Pay $495.79k)
  • Dr. Ryan Zeidan Ph.D., Chief Devel. Officer (Age 40, Pay $511.69k)
  • Dr. Gary Hammer M.D., Ph.D., Co-Founder and Chairman of Scientific Advisory Board
  • Ms. Tamara Lynn Joseph, Gen. Counsel & Corp. Sec. (Age 57)

What is Millendo Therapeutics' stock symbol?

Millendo Therapeutics trades on the NASDAQ under the ticker symbol "MLND."

Who are Millendo Therapeutics' major shareholders?

Millendo Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.23%), State Street Corp (0.94%), Soleus Capital Management L.P. (0.78%), Geode Capital Management LLC (0.75%), JPMorgan Chase & Co. (0.18%) and Bank of New York Mellon Corp (0.15%).

Which major investors are selling Millendo Therapeutics stock?

MLND stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC.

Which major investors are buying Millendo Therapeutics stock?

MLND stock was purchased by a variety of institutional investors in the last quarter, including Soleus Capital Management L.P., BlackRock Inc., Geode Capital Management LLC, Dupont Capital Management Corp, Los Angeles Capital Management & Equity Research Inc., Trexquant Investment LP, Nuveen Asset Management LLC, and Wedbush Securities Inc..

How do I buy shares of Millendo Therapeutics?

Shares of MLND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Millendo Therapeutics' stock price today?

One share of MLND stock can currently be purchased for approximately $2.18.

How big of a company is Millendo Therapeutics?

Millendo Therapeutics has a market capitalization of $41.42 million and generates $290,000.00 in revenue each year. The company earns $-44,570,000.00 in net income (profit) each year or ($3.25) on an earnings per share basis. Millendo Therapeutics employs 37 workers across the globe.

What is Millendo Therapeutics' official website?

The official website for Millendo Therapeutics is www.millendo.com.

How can I contact Millendo Therapeutics?

Millendo Therapeutics' mailing address is 110 MILLER AVENUE SUITE 100, ANN ARBOR MI, 48104. The company can be reached via phone at 734-845-9000 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.